Key Points
- Ra Capital Management, Hemab Therapeutics’ major shareholder, bought 61,523 shares on June 16 for about $1.54 million at an average price of $24.98 per share. After the purchase, it held 6.44 million shares, worth roughly $161 million.
- The investor has been actively adding to its position with multiple recent buys in May and June, including a 2.675 million-share purchase on May 4. These transactions were disclosed in SEC filings, as required for large shareholders.
- Hemab Therapeutics stock was trading up 3.7% to $26.45, and analysts currently have a Buy consensus with an average price target of $41.40. The clinical-stage biotech reported a quarterly EPS of ($23.98) in its latest earnings release.
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) major shareholder Ra Capital Management, L.P. acquired 6,146 shares of the company's stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $24.89 per share, for a total transaction of $152,973.94. Following the completion of the purchase, the insider owned 6,383,114 shares of the company's stock, valued at approximately $158,875,707.46. This represents a 0.10% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, June 16th, Ra Capital Management, L.P. bought 61,523 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.98 per share, for a total transaction of $1,536,844.54.
- On Wednesday, May 20th, Ra Capital Management, L.P. acquired 996 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.94 per share, for a total transaction of $24,840.24.
- On Tuesday, May 19th, Ra Capital Management, L.P. purchased 3,802 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.97 per share, with a total value of $94,935.94.
- On Tuesday, May 12th, Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.90 per share, with a total value of $159,036.30.
- On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.81 per share, with a total value of $989,149.89.
- On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.98 per share, with a total value of $37,045.34.
- On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.46 per share, with a total value of $242,300.76.
- On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.60 per share, with a total value of $1,673,242.80.
- On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.63 per share, with a total value of $2,399,232.93.
- On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The stock was bought at an average price of $18.00 per share, with a total value of $48,150,000.00.
Hemab Therapeutics Trading Up 3.7%
NASDAQ:COAG opened at $26.45 on Thursday. Hemab Therapeutics Holdings, Inc. has a twelve month low of $23.00 and a twelve month high of $36.61.
Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last posted its earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on COAG shares. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a "buy" rating and a $39.00 price target for the company. Zacks Research upgraded shares of Hemab Therapeutics to a "hold" rating in a research report on Wednesday, May 27th. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a "buy" rating and a $36.00 target price for the company. Evercore began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued an "outperform" rating and a $50.00 price objective on the stock. Finally, HC Wainwright began coverage on Hemab Therapeutics in a research report on Wednesday. They set a "buy" rating and a $40.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $41.40.
Read Our Latest Research Report on COAG
About Hemab Therapeutics
(
Get Free Report)
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
